Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 8 November

Grady Wulff
December 8, 2022

Morning Bell 6 December

Sophia Mavridis
December 6, 2022

Closing Bell 5 December

Grady Wulff
December 5, 2022

Morning Bell 5 December

Grady Wulff
December 5, 2022

Weekly Wrap 2 December

Sophia Mavridis
December 2, 2022

Morning Bell 2 December

Sophia Mavridis
December 2, 2022

Closing Bell 1 December

Sophia Mavridis
December 1, 2022

Morning Bell 1 December

Sophia Mavridis
December 1, 2022

Closing Bell 30 November

Sophia Mavridis
November 30, 2022

Morning Bell 30 November

Grady Wulff
November 30, 2022

Closing Bell 29 November

Sophia Mavridis
November 29, 2022